Comparative economic analysis between drugs available in primary health care and in the Popular Pharmacy Program of Brazil in a Brazilian capital

Authors

DOI:

https://doi.org/10.30968/rbfhss.2023.144.0911

Abstract

Objective: To compare public expenditures on medications distributed in Primary Health Care through the Brazilian Unified Health System (SUS) with those provided by the PFPB in the city of Porto Alegre, RS. Methods: A cross-sectional economic analysis was conducted by examining the items available through the Municipal List of Essential Medications (REMUME) for the year 2020 and extracting data from the local bidding processes. The calculation factor considered the annual value of committed medications and the annual structural and human resource costs associated with maintaining all stages of pharmaceutical care, from procurement to medication dispensation, as detailed in the municipal management report. PFPB costs, in Brazilian Reais and US Dollars per pharmaceutical unit, for the same items available in the SUS, were determined in accordance with Ministry of Health ordinances No. 2,898 of November 3, 2021, and No. 5 of September 28, 2017. Results: A total of 16 medications were selected, and the overall difference between the costs incurred by the Municipal Government of Porto Alegre (PMPA) and the estimated costs of the PFPB amounted to R$ 6,503,221.20 ($1,245,827.82), approximately 1.77 times the annual cost incurred by the PMPA for all stages of pharmaceutical care, from procurement to medication dispensation. Sodium alendronate 70 mg was found to be the primary contributor to the cost differential among access to medications. In terms of annual expenditures, simvastatin 20 mg was identified as the medication incurring the highest costs for both the PMPA and the PFPB. Conclusion: The study revealed higher medication expenditures through the PFPB. The variance in logistical stages of medication distribution could be redirected towards expanding pharmaceutical services and improving structural aspects in Primary Health Care, thereby contributing to Rational Medication Use. This, in turn, may result in reduced costs associated with the treatment of medication-related morbidities.

Downloads

Download data is not yet available.

References

Planalto.gov.br. L8080. Available in: http://www.planalto.gov.br/ccivil_03/leis/l8080.htm. Accessed on: February 28, 2022.

Ministério da Saúde. Política Nacional de Medicamentos, 2001. Available in: https://bvsms.saude.gov.br/bvs/publicacoes/politica_medicamentos.pdf. Accessed on: February 28, 2022.

Ministério da Saúde. Saude.gov.br. Available in: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2017/ prc0006_03_10_2017.html#TITULOV. Accessed on: March 6, 2022.

Ministério da Saúde. Saude.gov.br. 2013. Available in: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/ prt1555_30_07_2013.html. Accessed on: April 19, 2022.

Pinto CDBS, Miranda ES, Emmerick ICM, et al. Medicine prices and availability in the Brazilian Popular Pharmacy Program. Revista de Saúde Pública. 2010;44(4):611-619. DOI:10.1590/s0034-89102010005000021.

Ministério da Saúde. Sobre o Programa. 2021. Available in: https://www.gov.br/saude/pt-br/assuntos/ assistencia-farmaceutica-no-sus/farmacia-popular-1/sobre-o-programa#:~:text=Em%2009%20de%20mar%- C3%A7o%20de,%E2%80%9CAqui%20Tem%20Farm%C3%A1cia%20Popular%E2%80%9D. Accessed on: March 6, 2022.

Mattos L, Silva R, Chaves G, et al. Assistência farmacêutica na atenção básica e Programa Farmácia Popular: a visão de gestores de esferas subnacionais do Sistema Único de Saúde. Saúde e Sociedade. 2019;28(1):287-298 . DOI:10.1590/s0104-12902019170442.

Santos-Pinto CDB, Costa NR, Osorio-de-Castro CG. Quem acessa o Programa Farmácia Popular do Brasil? Aspectos do fornecimento público de medicamentos. Ciência & Saúde Coletiva. 2011;16:2963-2973. DOI:10.1590/S1413-81232011000600034.

INESC. Orçamento Temático de Acesso a Medicamentos 2019- INESC. 2020. Available in: https://www.inesc.org.br/orcamen- to=-tematico-de-acesso-a-medicamentos2019-/#:~:textA%20%C3%BAltima%20edi%C3%A7%C3%A3o%20da%20s%C3%A9rie%20de%20publica%C3%A7%C3%B5es%20 mostra%20que%2C%20em,ano%20de%20in%C3%ADcio%20da%20s%C3%A9rie. Accessed on: March 6, 2022.

Garcia MM, Guerra AA Júnior, Acúrcio FA. Avaliação econômica dos Programas Rede Farmácia de Minas do SUS versus Farmácia Popular do Brasil. Ciência & Saúde Cole- tiva. 2017;22(1):221-233. DOI:10.1590/1413-81232017221.15912015.

Brasil. Ministério da Saúde. Os 10 anos do Programa Farmácia Popular do Brasil. In: VII Fórum Nacional de Assistência Farmacêutica. Brasília, DF: MS; 2014.

World Health Organization. The Pursuit of Responsible Use of Medicines: Sharing and Learning from Country Experiences. Genebra: WHO; 2012 Available in: http://apps.who.int/iris/bitstream/10665/75828/1/WHO_EMP_ MAR_2012.3_eng.pdf. Accessed on: April 9, 2022.

CONASS. Assistência Farmacêutica no SUS. 2015. Available in: https://www.conass.org.br/biblioteca/assistencia-farmaceutica-no-sus-2/. Accessed on: April 9, 2022.

Prefeitura de Porto Alegre. Relatório de Gestão. Available in: https://www2.portoalegre.rs.gov.br/sms/default.php?p_ secao=895. Accessed on: February 18, 2022.

Do Amaral GL, Olenike JE, Fernandes do Amaral LM, et al. Redução do ICMS sobre medicamentos: mais: estudo do impacto nos preços dos medicamentos ao consumidor após a redução da alíquota do ICMS no Estado do Paraná, e os reflexos na arrecadação deste tributo. São Paulo: SINDUSFARMA, Sindicato da Indústria de Produtos Farmacêuticos no Estado de São Paulo, 2012. Available in: https://sindusfarma.org.br/cadastro/public/uploads/publicacoes/arquivos/91/reducao_do_icms_sobre_medicamentos_baixa_resolucao.pdf. Accessed on: February 18, 2022.

BRASIL. Secretaria Especial do Tesouro e Orçamento (SETO). Departamento de Avaliação de Políticas Públicas (DEAP). Conselho de monitoramento e avaliação de políticas públicas. Comitê de monitoramento e avaliação de subsídios da união (CMAS). Relatório de Avaliação Política de Subsídio Tributário a Medicamentos. Ciclo 2021. Available in: https://www.gov.br/economia/pt-br/acesso-a-informacao/participacao-social/conselhos-e-orgaos-colegiados/cmap/politicas/2021/subsidios/medicamentos-relatorio-de-avaliacao.pdf. Accessed on: October 20, 2023.

Schmidt MI, Duncan BB, e Silva GA, et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet. 2011;377(9781): 1949-1961. DOI:10.1016/s0140-6736(11)60135-9.

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: pros and cons. Medicina Clínica. 2018150(10):398-402. DOI:10.1016/j.medcli.2017.11.030.

Da Silva RM, Caetano R. Costs of Public Pharmaceutical Services in Rio de Janeiro Compared to Farmácia Popular Program. Revista de Saúde Pública. 2016;50(0). DOI:10.1590/s1518-8787.2016050006605.

Boing A, Bof de Andrade F, Bertoldi A, et al. Prevalências e desigualdades no acesso aos medicamentos por usuários do Sistema Único de Saúde no Brasil em 2013 e 2019. Cad Saúde Pública. 2022. DOI:10.1590/0102-311XPT114721.

Published

2024-01-08

How to Cite

1.
ALMEIDA LA, PEDRAZZA GP, BELTRAMI NM, GNATTA D. Comparative economic analysis between drugs available in primary health care and in the Popular Pharmacy Program of Brazil in a Brazilian capital. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Jan.8 [cited 2024Feb.22];14(4):911. Available from: https://rbfhss.org.br/sbrafh/article/view/911

Issue

Section

ORIGINAL ARTICLES